Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that restrictions by health insurers and government health authorities to control expenses may hurt the malignant melanoma drug market. According to the new Pharmacor study entitled Malignant Melanoma, concern over spiraling costs of expensive biological therapies that provide only modest gains in overall survival leave physicians at odds about their therapeutic value.

"Current medical practice exhibits two schools of thought: clinicians who consider systemic biotherapy to be cost-effective and those who are not convinced because of the marginal improvement in disease-free survival that such therapy achieves," said Joanne Graham, Ph.D., analyst Decision Resources.

The study also finds that Celgene's Revimid will provide an effective, well-tolerated alternative to the cocktail of chemotherapy agents currently used as second-line treatment for patients with stage IV disease and will achieve sales of $62 million in 2013.

About Malignant Melanoma

The malignant melanoma drug market is devoid of therapies that can prevent progression to fatal disease. Complete responses in metastatic malignant melanoma are rare, and although disease-free survival in patients with metastatic malignant melanoma can be extended with current therapies, convincing data that demonstrate an extension in overall survival are lacking.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

European Rheumatoid Arthritis Drug Market Will Top $3 Billion in 2012

View Now